Menu Search
Equities

CorMedix Inc

19KA:BER

CorMedix Inc

Actions
  • Price (EUR)9.75
  • Today's Change-0.150 / -1.52%
  • Shares traded--
  • 1 Year change+188.46%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

  • Revenue in USD (TTM)12.26m
  • Net income in USD-46.15m
  • Incorporated2006
  • Employees82.00
  • Location
    CorMedix Inc300 Connell Drive, Suite 4200BERKELEY HEIGHTS 07922United StatesUSA
  • Phone+1 (908) 517-9500
  • Fax+1 (302) 636-5454
  • Websitehttps://cormedix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.